APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pharma Sustained Release Agent

Compare research editions
View pricing & licenses

Selected research

Industry Research

Pharma Sustained Release Agent Industry Research Report 2026

Report ID 174024640520 December 2025139 pages

Choose your research edition.

Industry ResearchPharma Sustained Release Agent Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharma Sustained Release Agent Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Pharma Sustained Release Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharma Sustained Release Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharma Sustained Release Agent Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Pharma Sustained Release Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Pharma Sustained Release Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Pharma Sustained Release Agent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Pharma Sustained Release Agent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Pharma Sustained Release Agent include Janssen Pharmaceuticals, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Novartis AG, Merck KGaA, Mylan N.V., Pfizer, GlaxoSmithKline and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Pharma Sustained Release Agent market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pharma Sustained Release Agent Market by Company

Janssen Pharmaceuticals

Teva Pharmaceutical Industries

Sun Pharmaceutical Industries

Novartis AG

Merck KGaA

Mylan N.V.

Pfizer

GlaxoSmithKline

AstraZeneca

Valeant Pharmaceuticals International

Mayne Pharma Group

International Flavors & Fragrances

Gattefosse

Evonik Industries

Croda International

BASF

Ashland Global

Allergan

Pharma Sustained Release Agent Segment by Type

Sugars

Gelatin

Minerals

Chitosan

Polymers

Pharma Sustained Release Agent Segment by Application

Pharmaceutical

Health Care

Others

Pharma Sustained Release Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharma Sustained Release Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharma Sustained Release Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharma Sustained Release Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Pharma Sustained Release Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Pharma Sustained Release Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Pharma Sustained Release Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pharma Sustained Release Agent Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Pharma Sustained Release Agent Sales (k tons) of Manufacturers (2021-2026) Table 7. Global Pharma Sustained Release Agent Sales Market Share by Manufacturers (2021-2026) Table 8. Global Pharma Sustained Release Agent Revenue of Manufacturers (2021-2026) Table 9. Global Pharma Sustained Release Agent Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Pharma Sustained Release Agent Average Price (US$/ton) of Manufacturers (2021-2026) Table 11. Global Pharma Sustained Release Agent Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Pharma Sustained Release Agent, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Pharma Sustained Release Agent, Product Type & Application Table 14. Global Pharma Sustained Release Agent Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Pharma Sustained Release Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Janssen Pharmaceuticals Company Information Table 19. Janssen Pharmaceuticals Business Overview Table 20. Janssen Pharmaceuticals Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 21. Janssen Pharmaceuticals Pharma Sustained Release Agent Product Portfolio Table 22. Janssen Pharmaceuticals Recent Developments Table 23. Teva Pharmaceutical Industries Company Information Table 24. Teva Pharmaceutical Industries Business Overview Table 25. Teva Pharmaceutical Industries Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 26. Teva Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio Table 27. Teva Pharmaceutical Industries Recent Developments Table 28. Sun Pharmaceutical Industries Company Information Table 29. Sun Pharmaceutical Industries Business Overview Table 30. Sun Pharmaceutical Industries Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 31. Sun Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio Table 32. Sun Pharmaceutical Industries Recent Developments Table 33. Novartis AG Company Information Table 34. Novartis AG Business Overview Table 35. Novartis AG Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 36. Novartis AG Pharma Sustained Release Agent Product Portfolio Table 37. Novartis AG Recent Developments Table 38. Merck KGaA Company Information Table 39. Merck KGaA Business Overview Table 40. Merck KGaA Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 41. Merck KGaA Pharma Sustained Release Agent Product Portfolio Table 42. Merck KGaA Recent Developments Table 43. Mylan N.V. Company Information Table 44. Mylan N.V. Business Overview Table 45. Mylan N.V. Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 46. Mylan N.V. Pharma Sustained Release Agent Product Portfolio Table 47. Mylan N.V. Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 51. Pfizer Pharma Sustained Release Agent Product Portfolio Table 52. Pfizer Recent Developments Table 53. GlaxoSmithKline Company Information Table 54. GlaxoSmithKline Business Overview Table 55. GlaxoSmithKline Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 56. GlaxoSmithKline Pharma Sustained Release Agent Product Portfolio Table 57. GlaxoSmithKline Recent Developments Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 61. AstraZeneca Pharma Sustained Release Agent Product Portfolio Table 62. AstraZeneca Recent Developments Table 63. Valeant Pharmaceuticals International Company Information Table 64. Valeant Pharmaceuticals International Business Overview Table 65. Valeant Pharmaceuticals International Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 66. Valeant Pharmaceuticals International Pharma Sustained Release Agent Product Portfolio Table 67. Valeant Pharmaceuticals International Recent Developments Table 68. Mayne Pharma Group Company Information Table 69. Mayne Pharma Group Business Overview Table 70. Mayne Pharma Group Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 71. Mayne Pharma Group Pharma Sustained Release Agent Product Portfolio Table 72. Mayne Pharma Group Recent Developments Table 73. International Flavors & Fragrances Company Information Table 74. International Flavors & Fragrances Business Overview Table 75. International Flavors & Fragrances Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 76. International Flavors & Fragrances Pharma Sustained Release Agent Product Portfolio Table 77. International Flavors & Fragrances Recent Developments Table 78. Gattefosse Company Information Table 79. Gattefosse Business Overview Table 80. Gattefosse Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 81. Gattefosse Pharma Sustained Release Agent Product Portfolio Table 82. Gattefosse Recent Developments Table 83. Evonik Industries Company Information Table 84. Evonik Industries Business Overview Table 85. Evonik Industries Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 86. Evonik Industries Pharma Sustained Release Agent Product Portfolio Table 87. Evonik Industries Recent Developments Table 88. Croda International Company Information Table 89. Croda International Business Overview Table 90. Croda International Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 91. Croda International Pharma Sustained Release Agent Product Portfolio Table 92. Croda International Recent Developments Table 93. BASF Company Information Table 94. BASF Business Overview Table 95. BASF Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 96. BASF Pharma Sustained Release Agent Product Portfolio Table 97. BASF Recent Developments Table 98. Ashland Global Company Information Table 99. Ashland Global Business Overview Table 100. Ashland Global Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 101. Ashland Global Pharma Sustained Release Agent Product Portfolio Table 102. Ashland Global Recent Developments Table 103. Allergan Company Information Table 104. Allergan Business Overview Table 105. Allergan Pharma Sustained Release Agent Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 106. Allergan Pharma Sustained Release Agent Product Portfolio Table 107. Allergan Recent Developments Table 108. Global Pharma Sustained Release Agent Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Pharma Sustained Release Agent Sales by Region (2021-2026) & (k tons) Table 110. Global Pharma Sustained Release Agent Sales Market Share by Region (2021-2026) Table 111. Global Pharma Sustained Release Agent Sales by Region (2027-2032) & (k tons) Table 112. Global Pharma Sustained Release Agent Sales Market Share by Region (2027-2032) Table 113. Global Pharma Sustained Release Agent Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Pharma Sustained Release Agent Revenue Market Share by Region (2021-2026) Table 115. Global Pharma Sustained Release Agent Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Pharma Sustained Release Agent Revenue Market Share by Region (2027-2032) Table 117. North America Pharma Sustained Release Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 119. North America Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 120. North America Pharma Sustained Release Agent Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Pharma Sustained Release Agent Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Pharma Sustained Release Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 124. Europe Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 125. Europe Pharma Sustained Release Agent Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Pharma Sustained Release Agent Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Pharma Sustained Release Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 129. Asia Pacific Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 130. Asia Pacific Pharma Sustained Release Agent Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Pharma Sustained Release Agent Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Pharma Sustained Release Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 134. South America Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 135. South America Pharma Sustained Release Agent Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Pharma Sustained Release Agent Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Pharma Sustained Release Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 139. Middle East and Africa Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 140. Middle East and Africa Pharma Sustained Release Agent Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Pharma Sustained Release Agent Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Pharma Sustained Release Agent Sales by Type (2021-2026) & (k tons) Table 143. Global Pharma Sustained Release Agent Sales by Type (2027-2032) & (k tons) Table 144. Global Pharma Sustained Release Agent Sales Market Share by Type (2021-2026) Table 145. Global Pharma Sustained Release Agent Sales Market Share by Type (2027-2032) Table 146. Global Pharma Sustained Release Agent Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Pharma Sustained Release Agent Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Pharma Sustained Release Agent Revenue Market Share by Type (2021-2026) Table 149. Global Pharma Sustained Release Agent Revenue Market Share by Type (2027-2032) Table 150. Global Pharma Sustained Release Agent Price by Type (2021-2026) & (US$/ton) Table 151. Global Pharma Sustained Release Agent Price by Type (2027-2032) & (US$/ton) Table 152. Global Pharma Sustained Release Agent Sales by Application (2021-2026) & (k tons) Table 153. Global Pharma Sustained Release Agent Sales by Application (2027-2032) & (k tons) Table 154. Global Pharma Sustained Release Agent Sales Market Share by Application (2021-2026) Table 155. Global Pharma Sustained Release Agent Sales Market Share by Application (2027-2032) Table 156. Global Pharma Sustained Release Agent Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Pharma Sustained Release Agent Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Pharma Sustained Release Agent Revenue Market Share by Application (2021-2026) Table 159. Global Pharma Sustained Release Agent Revenue Market Share by Application (2027-2032) Table 160. Global Pharma Sustained Release Agent Price by Application (2021-2026) & (US$/ton) Table 161. Global Pharma Sustained Release Agent Price by Application (2027-2032) & (US$/ton) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Pharma Sustained Release Agent Distributors List Table 165. Pharma Sustained Release Agent Customers List Table 166. Pharma Sustained Release Agent Industry Trends Table 167. Pharma Sustained Release Agent Industry Drivers Table 168. Pharma Sustained Release Agent Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pharma Sustained Release Agent Product Image Figure 5. Global Pharma Sustained Release Agent Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Pharma Sustained Release Agent Market Size (2021-2032) & (US$ Million) Figure 7. Global Pharma Sustained Release Agent Sales (2021-2032) & (k tons) Figure 8. Global Pharma Sustained Release Agent Average Price (US$/ton) & (2021-2032) Figure 9. Sugars Product Image Figure 10. Gelatin Product Image Figure 11. Minerals Product Image Figure 12. Chitosan Product Image Figure 13. Polymers Product Image Figure 14. Pharmaceutical Product Image Figure 15. Health Care Product Image Figure 16. Others Product Image Figure 17. Global Pharma Sustained Release Agent Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Pharma Sustained Release Agent, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Pharma Sustained Release Agent Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Pharma Sustained Release Agent Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Pharma Sustained Release Agent Sales by Region in 2025 Figure 23. Global Pharma Sustained Release Agent Revenue by Region in 2025 Figure 24. North America Pharma Sustained Release Agent Market Size by Country in 2025 Figure 25. North America Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 26. North America Pharma Sustained Release Agent Revenue Market Share by Country (2021-2032) Figure 27. United States Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Pharma Sustained Release Agent Market Size by Country in 2025 Figure 31. Europe Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 32. Europe Pharma Sustained Release Agent Revenue Market Share by Country (2021-2032) Figure 33. Germany Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Pharma Sustained Release Agent Market Size by Country in 2025 Figure 44. Asia Pacific Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Pharma Sustained Release Agent Revenue Market Share by Country (2021-2032) Figure 46. China Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Pharma Sustained Release Agent Market Size by Country in 2025 Figure 55. South America Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 56. South America Pharma Sustained Release Agent Revenue Market Share by Country (2021-2032) Figure 57. Brazil Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Pharma Sustained Release Agent Market Size by Country in 2025 Figure 61. Middle East and Africa Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Pharma Sustained Release Agent Revenue Market Share by Country (2021-2032) Figure 63. Egypt Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Pharma Sustained Release Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Pharma Sustained Release Agent Sales Market Share by Type (2021-2032) Figure 69. Global Pharma Sustained Release Agent Revenue Market Share by Type (2021-2032) Figure 70. Global Pharma Sustained Release Agent Price (US$/ton) by Type (2021-2032) Figure 71. Global Pharma Sustained Release Agent Sales Market Share by Application (2021-2032) Figure 72. Global Pharma Sustained Release Agent Revenue Market Share by Application (2021-2032) Figure 73. Global Pharma Sustained Release Agent Price (US$/ton) by Application (2021-2032) Figure 74. Pharma Sustained Release Agent Value Chain Figure 75. Pharma Sustained Release Agent Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Pharma Sustained Release Agent Industry Opportunities and Challenges

Scope & coverage.

Types
  • Sugars
  • Gelatin
  • Minerals
  • Chitosan
  • Polymers
Applications
  • Pharmaceutical
  • Health Care
  • Others
Companies covered
  • Janssen Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Novartis AG
  • Merck KGaA
  • Mylan N.V.
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Valeant Pharmaceuticals International
  • Mayne Pharma Group
  • International Flavors & Fragrances
  • Gattefosse
  • Evonik Industries
  • Croda International
  • BASF
  • Ashland Global
  • Allergan

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Pharma Sustained Release Agent Market Size (2021-2032)
  4. 2.2.2 Global Pharma Sustained Release Agent Sales (2021-2032)
  5. 2.2.3 Global Pharma Sustained Release Agent Market Average Price (2021-2032)
  6. 2.3 Pharma Sustained Release Agent by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Sugars
  9. 2.3.3 Gelatin
  10. 2.3.4 Minerals
  11. 2.3.5 Chitosan
  12. 2.3.6 Polymers
  13. 2.4 Pharma Sustained Release Agent by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Pharmaceutical
  16. 2.4.3 Health Care
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Pharma Sustained Release Agent Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Pharma Sustained Release Agent Sales (k tons) of Manufacturers (2021-2026)
  3. 3.3 Global Pharma Sustained Release Agent Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Pharma Sustained Release Agent Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Pharma Sustained Release Agent Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Pharma Sustained Release Agent, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Pharma Sustained Release Agent, Product Type & Application
  8. 3.8 Global Manufacturers of Pharma Sustained Release Agent, Established Date
  9. 3.9 Global Pharma Sustained Release Agent Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Janssen Pharmaceuticals
  2. 4.1.1 Janssen Pharmaceuticals Company Information
  3. 4.1.2 Janssen Pharmaceuticals Business Overview
  4. 4.1.3 Janssen Pharmaceuticals Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Janssen Pharmaceuticals Pharma Sustained Release Agent Product Portfolio
  6. 4.1.5 Janssen Pharmaceuticals Recent Developments
  7. 4.2 Teva Pharmaceutical Industries
  8. 4.2.1 Teva Pharmaceutical Industries Company Information
  9. 4.2.2 Teva Pharmaceutical Industries Business Overview
  10. 4.2.3 Teva Pharmaceutical Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Teva Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio
  12. 4.2.5 Teva Pharmaceutical Industries Recent Developments
  13. 4.3 Sun Pharmaceutical Industries
  14. 4.3.1 Sun Pharmaceutical Industries Company Information
  15. 4.3.2 Sun Pharmaceutical Industries Business Overview
  16. 4.3.3 Sun Pharmaceutical Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sun Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio
  18. 4.3.5 Sun Pharmaceutical Industries Recent Developments
  19. 4.4 Novartis AG
  20. 4.4.1 Novartis AG Company Information
  21. 4.4.2 Novartis AG Business Overview
  22. 4.4.3 Novartis AG Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis AG Pharma Sustained Release Agent Product Portfolio
  24. 4.4.5 Novartis AG Recent Developments
  25. 4.5 Merck KGaA
  26. 4.5.1 Merck KGaA Company Information
  27. 4.5.2 Merck KGaA Business Overview
  28. 4.5.3 Merck KGaA Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Merck KGaA Pharma Sustained Release Agent Product Portfolio
  30. 4.5.5 Merck KGaA Recent Developments
  31. 4.6 Mylan N.V.
  32. 4.6.1 Mylan N.V. Company Information
  33. 4.6.2 Mylan N.V. Business Overview
  34. 4.6.3 Mylan N.V. Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Mylan N.V. Pharma Sustained Release Agent Product Portfolio
  36. 4.6.5 Mylan N.V. Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Pharma Sustained Release Agent Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 GlaxoSmithKline
  44. 4.8.1 GlaxoSmithKline Company Information
  45. 4.8.2 GlaxoSmithKline Business Overview
  46. 4.8.3 GlaxoSmithKline Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 GlaxoSmithKline Pharma Sustained Release Agent Product Portfolio
  48. 4.8.5 GlaxoSmithKline Recent Developments
  49. 4.9 AstraZeneca
  50. 4.9.1 AstraZeneca Company Information
  51. 4.9.2 AstraZeneca Business Overview
  52. 4.9.3 AstraZeneca Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AstraZeneca Pharma Sustained Release Agent Product Portfolio
  54. 4.9.5 AstraZeneca Recent Developments
  55. 4.10 Valeant Pharmaceuticals International
  56. 4.10.1 Valeant Pharmaceuticals International Company Information
  57. 4.10.2 Valeant Pharmaceuticals International Business Overview
  58. 4.10.3 Valeant Pharmaceuticals International Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Valeant Pharmaceuticals International Pharma Sustained Release Agent Product Portfolio
  60. 4.10.5 Valeant Pharmaceuticals International Recent Developments
  61. 4.11 Mayne Pharma Group
  62. 4.11.1 Mayne Pharma Group Company Information
  63. 4.11.2 Mayne Pharma Group Business Overview
  64. 4.11.3 Mayne Pharma Group Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Mayne Pharma Group Pharma Sustained Release Agent Product Portfolio
  66. 4.11.5 Mayne Pharma Group Recent Developments
  67. 4.12 International Flavors & Fragrances
  68. 4.12.1 International Flavors & Fragrances Company Information
  69. 4.12.2 International Flavors & Fragrances Business Overview
  70. 4.12.3 International Flavors & Fragrances Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 International Flavors & Fragrances Pharma Sustained Release Agent Product Portfolio
  72. 4.12.5 International Flavors & Fragrances Recent Developments
  73. 4.13 Gattefosse
  74. 4.13.1 Gattefosse Company Information
  75. 4.13.2 Gattefosse Business Overview
  76. 4.13.3 Gattefosse Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Gattefosse Pharma Sustained Release Agent Product Portfolio
  78. 4.13.5 Gattefosse Recent Developments
  79. 4.14 Evonik Industries
  80. 4.14.1 Evonik Industries Company Information
  81. 4.14.2 Evonik Industries Business Overview
  82. 4.14.3 Evonik Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Evonik Industries Pharma Sustained Release Agent Product Portfolio
  84. 4.14.5 Evonik Industries Recent Developments
  85. 4.15 Croda International
  86. 4.15.1 Croda International Company Information
  87. 4.15.2 Croda International Business Overview
  88. 4.15.3 Croda International Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Croda International Pharma Sustained Release Agent Product Portfolio
  90. 4.15.5 Croda International Recent Developments
  91. 4.16 BASF
  92. 4.16.1 BASF Company Information
  93. 4.16.2 BASF Business Overview
  94. 4.16.3 BASF Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 BASF Pharma Sustained Release Agent Product Portfolio
  96. 4.16.5 BASF Recent Developments
  97. 4.17 Ashland Global
  98. 4.17.1 Ashland Global Company Information
  99. 4.17.2 Ashland Global Business Overview
  100. 4.17.3 Ashland Global Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Ashland Global Pharma Sustained Release Agent Product Portfolio
  102. 4.17.5 Ashland Global Recent Developments
  103. 4.18 Allergan
  104. 4.18.1 Allergan Company Information
  105. 4.18.2 Allergan Business Overview
  106. 4.18.3 Allergan Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Allergan Pharma Sustained Release Agent Product Portfolio
  108. 4.18.5 Allergan Recent Developments
5 Global Pharma Sustained Release Agent Market Scenario by Region
  1. 5.1 Global Pharma Sustained Release Agent Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Pharma Sustained Release Agent Sales by Region: 2021-2032
  3. 5.2.1 Global Pharma Sustained Release Agent Sales by Region: 2021-2026
  4. 5.2.2 Global Pharma Sustained Release Agent Sales by Region: 2027-2032
  5. 5.3 Global Pharma Sustained Release Agent Revenue by Region: 2021-2032
  6. 5.3.1 Global Pharma Sustained Release Agent Revenue by Region: 2021-2026
  7. 5.3.2 Global Pharma Sustained Release Agent Revenue by Region: 2027-2032
  8. 5.4 North America Pharma Sustained Release Agent Market Facts & Figures by Country
  9. 5.4.1 North America Pharma Sustained Release Agent Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Pharma Sustained Release Agent Sales by Country (2021-2032)
  11. 5.4.3 North America Pharma Sustained Release Agent Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Pharma Sustained Release Agent Market Facts & Figures by Country
  16. 5.5.1 Europe Pharma Sustained Release Agent Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Pharma Sustained Release Agent Sales by Country (2021-2032)
  18. 5.5.3 Europe Pharma Sustained Release Agent Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Pharma Sustained Release Agent Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Pharma Sustained Release Agent Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Pharma Sustained Release Agent Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Pharma Sustained Release Agent Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Pharma Sustained Release Agent Market Facts & Figures by Country
  41. 5.7.1 South America Pharma Sustained Release Agent Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Pharma Sustained Release Agent Sales by Country (2021-2032)
  43. 5.7.3 South America Pharma Sustained Release Agent Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Pharma Sustained Release Agent Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Pharma Sustained Release Agent Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Pharma Sustained Release Agent Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Pharma Sustained Release Agent Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Pharma Sustained Release Agent Sales by Type (2021-2032)
  2. 6.1.1 Global Pharma Sustained Release Agent Sales by Type (2021-2032) & (k tons)
  3. 6.1.2 Global Pharma Sustained Release Agent Sales Market Share by Type (2021-2032)
  4. 6.2 Global Pharma Sustained Release Agent Revenue by Type (2021-2032)
  5. 6.2.1 Global Pharma Sustained Release Agent Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Pharma Sustained Release Agent Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Pharma Sustained Release Agent Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Pharma Sustained Release Agent Sales by Application (2021-2032)
  2. 7.1.1 Global Pharma Sustained Release Agent Sales by Application (2021-2032) & (k tons)
  3. 7.1.2 Global Pharma Sustained Release Agent Sales Market Share by Application (2021-2032)
  4. 7.2 Global Pharma Sustained Release Agent Revenue by Application (2021-2032)
  5. 7.2.1 Global Pharma Sustained Release Agent Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Pharma Sustained Release Agent Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Pharma Sustained Release Agent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Pharma Sustained Release Agent Value Chain Analysis
  2. 8.1.1 Pharma Sustained Release Agent Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Pharma Sustained Release Agent Production Mode & Process
  5. 8.2 Pharma Sustained Release Agent Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Pharma Sustained Release Agent Distributors
  8. 8.2.3 Pharma Sustained Release Agent Customers
9 Global Pharma Sustained Release Agent Analyzing Market Dynamics
  1. 9.1 Pharma Sustained Release Agent Industry Trends
  2. 9.2 Pharma Sustained Release Agent Industry Drivers
  3. 9.3 Pharma Sustained Release Agent Industry Opportunities and Challenges
  4. 9.4 Pharma Sustained Release Agent Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst